Michael Geffner
Equibles does not estimate personal net worth.
About Michael Geffner
Immunovant, Inc. reported in an 8-K filed November 21, 2025 that Michael Geffner was terminated as Chief Medical Officer, effective November 21, 2025. The proxy statement of Immunovant, Inc. reports total compensation of $5,254,089 for Michael Geffner in fiscal 2026, including a base salary of $345,521. Disclosed compensation is on record for 2 fiscal years.
“Michael Geffner, M.D., M.B.A., ceased serving as the Chief Medical Officer of Immunovant, Inc. (the “Company”), effective November 21, 2025 (“Separation Date”), in connection with the Company’s restructuring of its R&D leadership structure under the Company’s Chief Executive Officer, Eric Venker, M.D., PharmD.”
Affiliation history
-
Immunovant, Inc. (IMVT)
Proxy statement
Start not stated–2025-11-21
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2026 | Immunovant, Inc. (IMVT) | Former Chief Medical Officer | $345,521 | $5,254,089 |
| 2025 | Immunovant, Inc. (IMVT) | Chief Medical Officer | $518,000 | $4,051,027 |